Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

SPECIAL REPORT: Can Innovation Supplant Convention in Sarcoidosis Treatment?

Published by: Decision Resources

Published: Sep. 23, 2009 - 24 Pages


Table of Contents


Executive Summary

Strategic Considerations

Stakeholder Implications

Introduction

Overview of Sarcoidosis

Symptoms

Pathophysiology and Etiology

Diagnosis

Epidemiology

Overview

Disease Defi nition

Methods

Subpopulations

Current Therapies

Corticosteroids

Methotrexate

Antimalarials

TNF-Alpha Inhibitors

Other Treatments

Emerging Therapies

Academic Research

Agents Seeking Approval for Sarcoidosis: Celgene’s Apremilast, Centocor/Medarex’s

Stelara, and MondoBiotech/Biogen Idec’s Aviptadil

Outlook

Bibliography


Tables

1. The Scadding Criteria for Sarcoidosis Staging

2. Current Therapies Used in the Treatment of Sarcoidosis

3. Academic- and Government-Initiated Clinical Trials in Sarcoidosis

4. Agents in Development for the Treatment of Sarcoidosis

5. Sales of Agents to Treat Sarcoidosis in the United States, 2008

Figures

1. Granuloma Formation in Sarcoidosis

2. Diagnosed Incidence of Sarcoidosis in the United States, 2008-2018

Abstract

Introduction

“I’d love there to be a better agent,” says a thought leader on the current state of sarcoidosis treatment. Many sarcoidosis patients require little or no treatment, but patients with chronic disease need a therapy that is safer than the corticosteroids that have become the mainstay treatment for the disease. Because substantial market constraints have limited development in this therapeutic area, only a few novel agents are in the pipeline. However, opportunity remains for an agent that can address some of the unmet needs in this market.

Questions Answered in This Report
    Sarcoidosis is an infl ammatory disease that is hallmarked by
  • the development of granulomas. What organ
    • systems are affected by sarcoidosis? How is the disease diagnosed? What is the prognosis for patients with sarcoidosis?
  • Sarcoidosis affects only a small percentage of the population. How many people were hospitalized with
    • sarcoidosis in 2008? Is this population expected to grow?
  • Patients with chronic sarcoidosis will require multiple treatment courses throughout their lifetime. What
    • are the current treatments for sarcoidosis? What are their benefi ts and drawbacks? How do emerging treatments compare with current offerings?
  • Reimbursement challenges loom large in this market. What effect are they having on sales? How might
    • companies overcome these challenges? What are the ideal characteristics of an agent positioned to capture the sarcoidosis market?
Scope
  • Overview of sarcoidosis: Pathophysiology and etiology, symptoms, diagnosis.
  • Epidemiology: Decision Resources epidemiology analysis of the diagnosed incidence and the
    • number of patients hospitalized with sarcoidosis in the United States, 2008-2018.
  • Current treatments: Corticosteroids, methotrexate, antimalarials, TNF-á inhibitors.
  • Emerging treatments: Celgene’s apremilast, MondoBiotech/Biogen Idec’s aviptadil, Centocor/
    • Medarex’s Stelara, ongoing academic research.
  • Market: 2008 sales, opportunities and challenges for emerging agents, remaining unmet need,
    • outlook for the sarcoidosis market.
  • Primary research: Interviews with thought leaders in sarcoidosis.


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2009